当前位置：
首页
>
成果及论文
成果及论文
- Han ZX, Liu J, Zhang WL, et al. Cardia and non-cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta-analysis, and estimation of population attributable fraction. Helicobacter. 2023 Jan 16:e12950.
- Duan M, Li YY, Liu J, Zhang WL, et al. Transmission Routes and Patterns of Helicobacter pylori. Helicobacter. 2023.
- Kong QZ, Li YY, Li RL, et al. Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study. Helicobacter, 2022, e12912.
- Han ZX, Li YY, Kong QZ, et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022;00:e12930.
- Ding YM, Li YY, Liu J, et al. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med. 2022 Dec 20.
- Zhang WL, Li YY, Liu J, et al. Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional survey. J Dig Dis. 2022;10.1111/1751-2980.13119.
- Zha J, Li YY, Qu JY, et al. Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter, 2022 Feb, 12; e12880.
- Lin BS, Li YY, Qiao C, et al. Implementation of WeChat-based patient-doctor interaction in the management of Helicobacter pylori infection: A propensity score matching analysis. J Dig Dis. 2022 Jul 12.
- Han ZX, Li YY, Li YQ. Helicobacter pylori, gastrointestinal microbiota, and immunotherapy. Helicobacter. 2022 Dec 7:e12942.
- Wang J, Li YY, Lin MJ, et al. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis. J Dig Dis. 2023 Jan;24(1):19-27.
- Ding YM, Li YY. Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication? Clin Exp Med. 2023 Nov;23(7):4037-4039.
- Zeng SY, Wang J, Liu J, et al. Efficacy and safety of a 14-day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study.J Gastroenterol Hepatol. 2023; 38(12): 2097-2103.
- Wu XQ, Duan M, Kong QZ, et al. Clarifying Varied Helicobacter pylori Eradication Therapies: A Comprehensive Review. Helicobacter. 2024.
- Kong Q, Ju K, Wan M, et al. Comparative Analysis of Large Language Models in Medical Counseling: A Focus on Helicobacter Pylori Infection. Helicobacter. 2024;29:e13055.
- Ju K, Kong Q, Li Y, et al. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis. Helicobacter. 2024;29:e13054.